Results of interferon-alfa therapy in patients with Behçet uveitis
To report on the results of interferon-alpha 2a (IFNalpha) treatment in patients with Behçet uveitis unresponsive to conventional immunosuppressive therapy. We retrospectively analyzed the medical records of 44 patients who had been treated with IFNalpha between September 2001 and May 2005. The init...
Gespeichert in:
| Veröffentlicht in: | Graefe's archive for clinical and experimental ophthalmology 2006-12, Vol.244 (12), p.1692-1695 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1695 |
|---|---|
| container_issue | 12 |
| container_start_page | 1692 |
| container_title | Graefe's archive for clinical and experimental ophthalmology |
| container_volume | 244 |
| creator | Tugal-Tutkun, Ilknur Güney-Tefekli, Esra Urgancioglu, Meri |
| description | To report on the results of interferon-alpha 2a (IFNalpha) treatment in patients with Behçet uveitis unresponsive to conventional immunosuppressive therapy.
We retrospectively analyzed the medical records of 44 patients who had been treated with IFNalpha between September 2001 and May 2005. The initial dose of IFNalpha was 6 MU/day in 37 patients (84.1%) and 3 MU/day in 7 patients (15.9%), and was gradually tapered after ocular inflammation was suppressed. Immunosuppressive agents were discontinued. Oral corticosteroids were discontinued or maintained at a dosage of less than 10 mg prednisone equivalent per day. Main outcome measures were recurrence of posterior or panuveitis attacks and changes in visual acuity.
Sixteen patients (36.4%) remained relapse free during treatment, whereas 28 (63.6%) patients had recurrent uveitis attacks. Four of these were considered treatment failures and were switched to other treatments. In the remaining 40 patients, the mean duration of treatment was 12.4+/-10.8 months (range 3-45 months). In 9 of 40 patients (22.5%) treatment could be discontinued 22.2+/-13.4 months after therapy, and 8 (20%) of these patients had sustained remission for up to 24 months. Three patients (7.5%) were switched to other therapies because of side effects. The frequency of uveitis attacks per 6 months was reduced from 1.6+/-1.2 to 0.8+/-0.9 in 26 patients who had a minimum follow-up of 6 months before and after IFNalpha therapy (p |
| doi_str_mv | 10.1007/s00417-006-0346-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68358996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1169988831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-2b2d0372c6345a419f0cd5fb4c57b090ec43765d1c1035181fc4cae196cf85933</originalsourceid><addsrcrecordid>eNpdkM1KxDAUhYMozjj6AG6kuHAXvWmapF3q4B8MCKIwu5CmCdOh09YkVfpEPogvZoYZEFxduHzncPgQOidwTQDEjQfIiMAAHAPNOB4P0JRklGEB6fIQTUGkBOc0XU7QifdriDhl5BhNCOeCEsqmaP5q_NAEn3Q2qdtgnDWua7FqrErCyjjVj_Gf9CrUpo3YVx1WyZ1Z_XybkAyfpg61P0VHVjXenO3vDL0_3L_Nn_Di5fF5frvAmqY84LRMK6Ai1ZxmTGWksKArZstMM1FCAUZnVHBWEU0gzsyJ1ZlWhhRc25wVlM7Q1a63d93HYHyQm9pr0zSqNd3gJc8py4uCR_DyH7juBtfGbTKlIArCII8Q2UHadd47Y2Xv6o1yoyQgt3rlTq-MeuVWrxxj5mJfPJQbU_0l9j7pL4dtdaE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230791508</pqid></control><display><type>article</type><title>Results of interferon-alfa therapy in patients with Behçet uveitis</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Tugal-Tutkun, Ilknur ; Güney-Tefekli, Esra ; Urgancioglu, Meri</creator><creatorcontrib>Tugal-Tutkun, Ilknur ; Güney-Tefekli, Esra ; Urgancioglu, Meri</creatorcontrib><description>To report on the results of interferon-alpha 2a (IFNalpha) treatment in patients with Behçet uveitis unresponsive to conventional immunosuppressive therapy.
We retrospectively analyzed the medical records of 44 patients who had been treated with IFNalpha between September 2001 and May 2005. The initial dose of IFNalpha was 6 MU/day in 37 patients (84.1%) and 3 MU/day in 7 patients (15.9%), and was gradually tapered after ocular inflammation was suppressed. Immunosuppressive agents were discontinued. Oral corticosteroids were discontinued or maintained at a dosage of less than 10 mg prednisone equivalent per day. Main outcome measures were recurrence of posterior or panuveitis attacks and changes in visual acuity.
Sixteen patients (36.4%) remained relapse free during treatment, whereas 28 (63.6%) patients had recurrent uveitis attacks. Four of these were considered treatment failures and were switched to other treatments. In the remaining 40 patients, the mean duration of treatment was 12.4+/-10.8 months (range 3-45 months). In 9 of 40 patients (22.5%) treatment could be discontinued 22.2+/-13.4 months after therapy, and 8 (20%) of these patients had sustained remission for up to 24 months. Three patients (7.5%) were switched to other therapies because of side effects. The frequency of uveitis attacks per 6 months was reduced from 1.6+/-1.2 to 0.8+/-0.9 in 26 patients who had a minimum follow-up of 6 months before and after IFNalpha therapy (p<0.05). There was a significant improvement in visual acuity and this was preserved throughout follow-up in 38 (95%) of 40 patients.
A partial or complete response was obtained with IFNalpha therapy in 91% of Turkish patients with Behçet uveitis refractory to conventional immunosuppressive treatment. Our results suggest that there may be differences in therapeutic efficacy and side-effect profile of IFNalpha in different patient populations. Comparative studies are needed to investigate this hypothesis.</description><identifier>ISSN: 0721-832X</identifier><identifier>EISSN: 1435-702X</identifier><identifier>DOI: 10.1007/s00417-006-0346-y</identifier><identifier>PMID: 16673135</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Adolescent ; Adult ; Aged ; Behcet Syndrome - drug therapy ; Female ; Humans ; Immunosuppressive Agents - therapeutic use ; Interferon-alpha - therapeutic use ; Male ; Middle Aged ; Ophthalmology ; Recombinant Proteins ; Recurrence ; Retrospective Studies ; Treatment Outcome ; Visual Acuity</subject><ispartof>Graefe's archive for clinical and experimental ophthalmology, 2006-12, Vol.244 (12), p.1692-1695</ispartof><rights>Springer-Verlag 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-2b2d0372c6345a419f0cd5fb4c57b090ec43765d1c1035181fc4cae196cf85933</citedby><cites>FETCH-LOGICAL-c326t-2b2d0372c6345a419f0cd5fb4c57b090ec43765d1c1035181fc4cae196cf85933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16673135$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tugal-Tutkun, Ilknur</creatorcontrib><creatorcontrib>Güney-Tefekli, Esra</creatorcontrib><creatorcontrib>Urgancioglu, Meri</creatorcontrib><title>Results of interferon-alfa therapy in patients with Behçet uveitis</title><title>Graefe's archive for clinical and experimental ophthalmology</title><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><description>To report on the results of interferon-alpha 2a (IFNalpha) treatment in patients with Behçet uveitis unresponsive to conventional immunosuppressive therapy.
We retrospectively analyzed the medical records of 44 patients who had been treated with IFNalpha between September 2001 and May 2005. The initial dose of IFNalpha was 6 MU/day in 37 patients (84.1%) and 3 MU/day in 7 patients (15.9%), and was gradually tapered after ocular inflammation was suppressed. Immunosuppressive agents were discontinued. Oral corticosteroids were discontinued or maintained at a dosage of less than 10 mg prednisone equivalent per day. Main outcome measures were recurrence of posterior or panuveitis attacks and changes in visual acuity.
Sixteen patients (36.4%) remained relapse free during treatment, whereas 28 (63.6%) patients had recurrent uveitis attacks. Four of these were considered treatment failures and were switched to other treatments. In the remaining 40 patients, the mean duration of treatment was 12.4+/-10.8 months (range 3-45 months). In 9 of 40 patients (22.5%) treatment could be discontinued 22.2+/-13.4 months after therapy, and 8 (20%) of these patients had sustained remission for up to 24 months. Three patients (7.5%) were switched to other therapies because of side effects. The frequency of uveitis attacks per 6 months was reduced from 1.6+/-1.2 to 0.8+/-0.9 in 26 patients who had a minimum follow-up of 6 months before and after IFNalpha therapy (p<0.05). There was a significant improvement in visual acuity and this was preserved throughout follow-up in 38 (95%) of 40 patients.
A partial or complete response was obtained with IFNalpha therapy in 91% of Turkish patients with Behçet uveitis refractory to conventional immunosuppressive treatment. Our results suggest that there may be differences in therapeutic efficacy and side-effect profile of IFNalpha in different patient populations. Comparative studies are needed to investigate this hypothesis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Behcet Syndrome - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ophthalmology</subject><subject>Recombinant Proteins</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Visual Acuity</subject><issn>0721-832X</issn><issn>1435-702X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkM1KxDAUhYMozjj6AG6kuHAXvWmapF3q4B8MCKIwu5CmCdOh09YkVfpEPogvZoYZEFxduHzncPgQOidwTQDEjQfIiMAAHAPNOB4P0JRklGEB6fIQTUGkBOc0XU7QifdriDhl5BhNCOeCEsqmaP5q_NAEn3Q2qdtgnDWua7FqrErCyjjVj_Gf9CrUpo3YVx1WyZ1Z_XybkAyfpg61P0VHVjXenO3vDL0_3L_Nn_Di5fF5frvAmqY84LRMK6Ai1ZxmTGWksKArZstMM1FCAUZnVHBWEU0gzsyJ1ZlWhhRc25wVlM7Q1a63d93HYHyQm9pr0zSqNd3gJc8py4uCR_DyH7juBtfGbTKlIArCII8Q2UHadd47Y2Xv6o1yoyQgt3rlTq-MeuVWrxxj5mJfPJQbU_0l9j7pL4dtdaE</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>Tugal-Tutkun, Ilknur</creator><creator>Güney-Tefekli, Esra</creator><creator>Urgancioglu, Meri</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20061201</creationdate><title>Results of interferon-alfa therapy in patients with Behçet uveitis</title><author>Tugal-Tutkun, Ilknur ; Güney-Tefekli, Esra ; Urgancioglu, Meri</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-2b2d0372c6345a419f0cd5fb4c57b090ec43765d1c1035181fc4cae196cf85933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Behcet Syndrome - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ophthalmology</topic><topic>Recombinant Proteins</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tugal-Tutkun, Ilknur</creatorcontrib><creatorcontrib>Güney-Tefekli, Esra</creatorcontrib><creatorcontrib>Urgancioglu, Meri</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tugal-Tutkun, Ilknur</au><au>Güney-Tefekli, Esra</au><au>Urgancioglu, Meri</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Results of interferon-alfa therapy in patients with Behçet uveitis</atitle><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>244</volume><issue>12</issue><spage>1692</spage><epage>1695</epage><pages>1692-1695</pages><issn>0721-832X</issn><eissn>1435-702X</eissn><abstract>To report on the results of interferon-alpha 2a (IFNalpha) treatment in patients with Behçet uveitis unresponsive to conventional immunosuppressive therapy.
We retrospectively analyzed the medical records of 44 patients who had been treated with IFNalpha between September 2001 and May 2005. The initial dose of IFNalpha was 6 MU/day in 37 patients (84.1%) and 3 MU/day in 7 patients (15.9%), and was gradually tapered after ocular inflammation was suppressed. Immunosuppressive agents were discontinued. Oral corticosteroids were discontinued or maintained at a dosage of less than 10 mg prednisone equivalent per day. Main outcome measures were recurrence of posterior or panuveitis attacks and changes in visual acuity.
Sixteen patients (36.4%) remained relapse free during treatment, whereas 28 (63.6%) patients had recurrent uveitis attacks. Four of these were considered treatment failures and were switched to other treatments. In the remaining 40 patients, the mean duration of treatment was 12.4+/-10.8 months (range 3-45 months). In 9 of 40 patients (22.5%) treatment could be discontinued 22.2+/-13.4 months after therapy, and 8 (20%) of these patients had sustained remission for up to 24 months. Three patients (7.5%) were switched to other therapies because of side effects. The frequency of uveitis attacks per 6 months was reduced from 1.6+/-1.2 to 0.8+/-0.9 in 26 patients who had a minimum follow-up of 6 months before and after IFNalpha therapy (p<0.05). There was a significant improvement in visual acuity and this was preserved throughout follow-up in 38 (95%) of 40 patients.
A partial or complete response was obtained with IFNalpha therapy in 91% of Turkish patients with Behçet uveitis refractory to conventional immunosuppressive treatment. Our results suggest that there may be differences in therapeutic efficacy and side-effect profile of IFNalpha in different patient populations. Comparative studies are needed to investigate this hypothesis.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>16673135</pmid><doi>10.1007/s00417-006-0346-y</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0721-832X |
| ispartof | Graefe's archive for clinical and experimental ophthalmology, 2006-12, Vol.244 (12), p.1692-1695 |
| issn | 0721-832X 1435-702X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68358996 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adolescent Adult Aged Behcet Syndrome - drug therapy Female Humans Immunosuppressive Agents - therapeutic use Interferon-alpha - therapeutic use Male Middle Aged Ophthalmology Recombinant Proteins Recurrence Retrospective Studies Treatment Outcome Visual Acuity |
| title | Results of interferon-alfa therapy in patients with Behçet uveitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T22%3A21%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Results%20of%20interferon-alfa%20therapy%20in%20patients%20with%20Beh%C3%A7et%20uveitis&rft.jtitle=Graefe's%20archive%20for%20clinical%20and%20experimental%20ophthalmology&rft.au=Tugal-Tutkun,%20Ilknur&rft.date=2006-12-01&rft.volume=244&rft.issue=12&rft.spage=1692&rft.epage=1695&rft.pages=1692-1695&rft.issn=0721-832X&rft.eissn=1435-702X&rft_id=info:doi/10.1007/s00417-006-0346-y&rft_dat=%3Cproquest_cross%3E1169988831%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230791508&rft_id=info:pmid/16673135&rfr_iscdi=true |